Qiagen NV (LTS:0RLT) Valuation Rank

View and export this data going back to 2008. Start your Free Trial

What is Qiagen NV Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Qiagen NV Valuation Rank Related Terms

Thank you for viewing the detailed overview of Qiagen NV's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Qiagen NV (LTS:0RLT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen NV (LTS:0RLT) » Definitions » Valuation Rank

Comparable Companies

EXAS NTRA CRL MEDP RVTY RDNT DGX SHC NEOG GH TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

QGEN:USA 1QGEN:Italy QIAd:UK QIA:Germany QGEN:Austria

Address

Hulsterweg 82, Venlo, LI, NLD, 5912 PL

Website

https://www.qiagen.com

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).